Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:LUCY NASDAQ:PAVM NYSE:RBOT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$0.34-4.4%$0.38$0.27▼$3.23$5.07M1.5785,318 shs28,566 shsLUCYInnovative Eyewear$0.77-1.1%$0.97$0.66▼$2.39$4.96M2.6663,833 shs51,749 shsPAVMPAVmed$4.62-1.3%$6.71$3.85▼$28.44$4.66M0.5823,362 shs3,582 shsRBOTVicarious Surgical$0.22+15.8%$0.61$0.16▼$13.75$1.57M1.7577,473 shs12,601 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-4.43%-0.18%-21.11%-49.03%-77.57%LUCYInnovative Eyewear-0.65%-11.05%-25.00%-29.82%-66.00%PAVMPAVmed-1.28%-7.60%-27.70%-48.32%-74.65%RBOTVicarious Surgical+18.92%-4.35%-77.84%-74.12%-97.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$0.34-4.4%$0.38$0.27▼$3.23$5.07M1.5785,318 shs28,566 shsLUCYInnovative Eyewear$0.77-1.1%$0.97$0.66▼$2.39$4.96M2.6663,833 shs51,749 shsPAVMPAVmed$4.62-1.3%$6.71$3.85▼$28.44$4.66M0.5823,362 shs3,582 shsRBOTVicarious Surgical$0.22+15.8%$0.61$0.16▼$13.75$1.57M1.7577,473 shs12,601 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-4.43%-0.18%-21.11%-49.03%-77.57%LUCYInnovative Eyewear-0.65%-11.05%-25.00%-29.82%-66.00%PAVMPAVmed-1.28%-7.60%-27.70%-48.32%-74.65%RBOTVicarious Surgical+18.92%-4.35%-77.84%-74.12%-97.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 2.00Hold$11.503,318.55% UpsideLUCYInnovative Eyewear 1.50ReduceN/AN/APAVMPAVmed 2.00Hold$56.001,112.12% UpsideRBOTVicarious Surgical 1.67Reduce$7.003,081.82% UpsideCurrent Analyst Ratings BreakdownLatest RBOT, PAVM, CLGN, and LUCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026CLGNCollPlant Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/8/2026PAVMPAVmed Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $56.006/3/2026LUCYInnovative Eyewear Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/22/2026CLGNCollPlant Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026LUCYInnovative Eyewear Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PAVMPAVmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/20/2026CLGNCollPlant Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PAVMPAVmed Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$510.00 ➝ $65.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$2.37M2.05N/AN/A$0.48 per share0.70LUCYInnovative Eyewear$2.66M1.84N/AN/A$1.69 per share0.45PAVMPAVmed$70K66.00N/AN/A($2.42) per share-1.91RBOTVicarious SurgicalN/AN/AN/AN/A$7.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$11.49M-$1.45N/AN/AN/A-683.68%-218.81%-139.28%8/20/2026 (Estimated)LUCYInnovative Eyewear-$7.59M-$1.69N/AN/AN/A-272.42%-83.37%-76.02%8/13/2026 (Estimated)PAVMPAVmed$400K-$37.40N/AN/AN/A-21,914.12%-146.19%-18.39%8/13/2026 (Estimated)RBOTVicarious Surgical-$63.22M-$6.69N/AN/AN/AN/A-184.13%-112.50%7/30/2026 (Estimated)Latest RBOT, PAVM, CLGN, and LUCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026CLGNCollPlant Biotechnologies-$0.2374-$0.23+$0.0074-$0.23$0.46 million$0.07 million5/14/2026Q1 2026LUCYInnovative Eyewear-$0.47-$0.37+$0.10-$0.37$0.70 million$0.77 million5/14/2026Q1 2026PAVMPAVmed-$0.69-$1.17-$0.48-$4.42$0.07 million$0.02 million3/25/2026Q4 2025LUCYInnovative Eyewear-$0.43-$0.28+$0.15-$0.28$1.20 million$0.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ALUCYInnovative EyewearN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ARBOTVicarious SurgicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A2.271.99LUCYInnovative EyewearN/A8.026.09PAVMPAVmed0.702.022.02RBOTVicarious SurgicalN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%LUCYInnovative Eyewear0.96%PAVMPAVmed19.93%RBOTVicarious Surgical47.27%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%LUCYInnovative Eyewear1.66%PAVMPAVmed13.40%RBOTVicarious Surgical9.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7014.41 million13.03 millionOptionableLUCYInnovative Eyewear96.40 million6.30 millionNot OptionablePAVMPAVmed901.00 million863,000No DataRBOTVicarious Surgical2107.12 million5.89 millionNo DataRBOT, PAVM, CLGN, and LUCY HeadlinesRecent News About These CompaniesVicarious Surgical (NYSE:RBOT) Trading Up 15.8% - Here's What Happened3 hours ago | americanbankingnews.comVicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical SettingMay 13, 2026 | globenewswire.comVicarious Surgical Reports First Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comVicarious Surgical Shareholders Approve Reverse Stock Split AuthorizationApril 8, 2026 | tipranks.comVicarious Surgical, Inc. Class AApril 7, 2026 | edition.cnn.comVicarious Surgical completes testing milestone for surgical robotMarch 30, 2026 | massdevice.comVicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia RepairMarch 30, 2026 | globenewswire.comVicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq ListingMarch 25, 2026 | globenewswire.com‘Why do we exist?’: Inside Stephen From’s business strategy to get Vicarious Surgical to the finish lineMarch 20, 2026 | massdevice.comVicarious Fights to Stay Afloat & Other Medtech NewsMarch 19, 2026 | mddionline.comMThis surgical robotics company sees opportunity in hernia repairMarch 19, 2026 | medicaldesignandoutsourcing.comMVicarious Surgical pursues Nasdaq listing, cuts cash burn to $19MMarch 16, 2026 | massdevice.comVicarious Surgical applies for Nasdaq listingMarch 16, 2026 | medtechdive.comMVicarious Fights to Right the ShipMarch 16, 2026 | mddionline.comMVicarious Surgical Announces Strategic Plan to Pursue Nasdaq ListingMarch 16, 2026 | uk.finance.yahoo.comVicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 9, 2026 | businesswire.comVicarious Surgical Implements Executive Salary Reductions, Maintains IncentivesMarch 6, 2026 | tipranks.comVicarious Surgical receives NYSE delisting noticeMarch 4, 2026 | medtechdive.comMVicarious Surgical Confronted with NYSE Delisting Amid Ongoing ChallengesMarch 4, 2026 | mddionline.comMVicarious Surgical Receives Delisting Notice From NYSEMarch 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRBOT, PAVM, CLGN, and LUCY Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$0.34 -0.02 (-4.43%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$0.35 +0.01 (+4.34%) As of 06/24/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Innovative Eyewear NASDAQ:LUCY$0.76 -0.01 (-1.14%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$0.75 -0.01 (-1.83%) As of 06/24/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.PAVmed NASDAQ:PAVM$4.62 -0.06 (-1.28%) Closing price 06/24/2026 03:51 PM EasternExtended Trading$4.66 +0.04 (+0.76%) As of 06/24/2026 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.Vicarious Surgical NYSE:RBOT$0.22 +0.03 (+15.79%) As of 06/24/2026 03:34 PM EasternVicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
